Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022–2024: results from the CLEAR registry
In Canada, ceftolozane/tazobactam is primarily used as directed therapy alone, or in combination, to treat MDR P. <i>aeruginosa</i> infections. Though mostly used to treat severely ill patients in the ICU, ceftolozane/tazobactam use in HABP and VABP is associated with relatively high microbiological/clinical cure rates and an excellent safety profile.
Authors
- Sergio Borgia (ORCID: https://orcid.org/0000-0002-7816-2929)
- Carlos Cervera (ORCID: https://orcid.org/0000-0002-0161-1749)
- Michel Savoie
- Melanie R. Baxter
- James A. Karlowsky (ORCID: https://orcid.org/0000-0002-1939-464X)
- Maggie Wong
- Yazdan Mirzanejad
- Rita Dhami
- Robert E. Ariano (ORCID: https://orcid.org/0000-0001-7021-4336)
- Andrew Walkty (ORCID: https://orcid.org/0000-0003-2880-2104)
- Carlo Tascini (ORCID: https://orcid.org/0000-0001-9625-6024)
- George G. Zhanel (ORCID: https://orcid.org/0000-0002-3238-0082)
- Justin Kosar
- Alex Serebryanskyy
- Neal Irfan
Institutions
- University of Udine (IT)
- University of British Columbia (CA)
- University of Alberta (CA)
- Fraser Health (CA)
- St. Boniface Hospital (CA)
- London Health Sciences Centre (CA)
- Royal University Hospital (CA)
- Health Sciences Centre (CA)
- William Osler Health System (CA)
- Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal (CA)
- Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal
- University of Manitoba (CA)
- Hamilton Health Sciences (CA)
Publication Details
- Journal
- Expert Review of Anti-infective Therapy
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1080/14787210.2024.2405930
- Citations
- 1
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.39